Cigna Group reports results for the quarter ended June 30 - Earnings Summary
Cigna Group reports results for the quarter ended June 30 - Earnings Summary
Cigna Group CI.N reported quarterly adjusted earnings of $7.78 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $7.20. The mean expectation of twenty four analysts for the quarter was for earnings of $7.60 per share. Wall Street expected results to range from $7.53 to $7.73 per share.
Revenue rose 6.5% to $71.56 billion from a year ago; analysts expected $70.34 billion.
Cigna Group's reported EPS for the quarter was $6.28.
The company reported quarterly net income of $1.66 billion.
Cigna Group shares had risen by 7.5% this quarter and gained 7.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 0.7% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the managed healthcare peer group is also "buy"
Wall Street's median 12-month price target for Cigna Group is $340.00, about 12.8% above its last closing price of $296.47
This summary was machine generated from LSEG data July 30 at 11:31 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 7.60 | 7.78 | Beat |
Mar. 31 2026 | 7.61 | 7.79 | Beat |
Dec. 31 2025 | 7.88 | 8.08 | Beat |
Sep. 30 2025 | 7.65 | 7.83 | Beat |
Recent news on Cigna group
See all newsBrief: Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits And Clinical Support Around Each Person, Improving Affordability And Outcomes
Most Americans support switch to Medicare for all health insurance
Analysis: Vance's fraud crackdown may raise costs for US health insurers, enrollees
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US RESEARCH ROUNDUP-Arxis, Cigna, Vylor